Lol-To The Moon - Tiger Brokers Online Investing Community

Like
Comment
Favorite

Boris628
2021-02-15

Lol

Summary of the 2020 financial reports of multinational pharmaceutical companies: Under the epidemic, let me show you how these pharmaceutical companies perform?

成为14家跨国药企中唯一一个出现下滑的企业。并且在2020年医保谈判中，O药未能进入中国的医保目录。2020年，辉瑞公司有5款药物的销量下降。据财报显示，肺癌靶向药劳拉替尼取得了不错的成绩，2020年获得了近80%的增长，是辉瑞新上市药品中表现最好的一个。阿斯利康：全年总收入266.17亿美元，成中国市场表现最好的跨国药企2月12日，阿斯利康公布了2020年全年财务报表，财报显示，全年营收为266.17亿美元，同比增长9%。

Summary of the 2020 financial reports of multinational pharmaceutical companies: Under the epidemic, let me show you how these pharmaceutical companies perform?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":382116633,"tweetId":"382116633","gmtCreate":1613382832522,"gmtModify":1704880209302,"author":{"id":3568930674369958,"idStr":"3568930674369958","authorId":3568930674369958,"authorIdStr":"3568930674369958","name":"Boris628","avatar":"https://static.tigerbbs.com/a8dfcfdfd3fab52796ba7c3129a89fe8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Lol</body></html>","htmlText":"<html><head></head><body>Lol</body></html>","text":"Lol","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/382116633","repostId":2111006332,"repostType":2,"repost":{"id":"2111006332","kind":"news","pubTimestamp":1613376887,"share":"https://ttm.financial/m/news/2111006332?lang=en_US&edition=fundamental","pubTime":"2021-02-15 16:14","market":"us","language":"zh","title":"Summary of the 2020 financial reports of multinational pharmaceutical companies: Under the epidemic, let me show you how these pharmaceutical companies perform?","url":"https://stock-news.laohu8.com/highlight/detail?id=2111006332","media":"健康时报客户端","summary":"成为14家跨国药企中唯一一个出现下滑的企业。并且在2020年医保谈判中，O药未能进入中国的医保目录。2020年，辉瑞公司有5款药物的销量下降。据财报显示，肺癌靶向药劳拉替尼取得了不错的成绩，2020年获得了近80%的增长，是辉瑞新上市药品中表现最好的一个。阿斯利康：全年总收入266.17亿美元，成中国市场表现最好的跨国药企2月12日，阿斯利康公布了2020年全年财务报表，财报显示，全年营收为266.17亿美元，同比增长9%。","content":"<html><body>Original title: Combing the financial reports of multinational pharmaceutical companies in 2020: Under the epidemic situation, let me show you how these pharmaceutical companies perform?In 2020, there was a global pandemic in COVID-19 pandemic. According to the latest data from the website of the World Health Organization, as of 15:35 CET on February 13, the cumulative number of confirmed cases of COVID-19 worldwide reached 108 million. Against this background, what kind of transcripts have multinational pharmaceutical companies handed over? Health Times reporters compiled them based on the 2020 financial reports released by major multinational pharmaceutical companies.<div><img src=\"http://k.sinaimg.cn/n/spider2021215/0/w640h2560/20210215/f1f8-kkciesq5521009.jpg/w720fin.jpg\"/></div><a href=\"https://laohu8.com/S/JNJ\">Johnson Johnson</a>: The total annual revenue was US $82.584 billion, due to the impact of the epidemic, the medical device business revenue dropped significantlyOn January 26, 2021, Johnson & Johnson announced its 2020 results, showing that its total revenue in 2020 was US $82.584 billion, a year-on-year increase of 0.6%; Among them, pharmaceutical business revenue and consumer health care business revenue both increased compared with last year, to US $45.572 billion and US $14.053 billion, respectively, an increase of +8% and 1.1%, but medical device business revenue was only US $22.959 billion, a decrease of 11.6%.Regarding the decline in medical device performance, Johnson & Johnson also said that it was mainly due to COVID-19 pandemic that a large number of surgical operations were delayed. The Health Times reporter also noticed that according to the financial report, Johnson & Johnson's medical device business achieved double-digit growth when the novel coronavirus pneumonia epidemic was well controlled in the fourth quarter.Roche：Full year revenueUS $59.6 billion, Roche Pharmaceuticals' Chinese market is growing steadilyOn February 4, Roche announced its 2020 results, with total annual revenue of US $59.6 billion, a year-on-year increase of 1%, of which pharmaceutical business revenue was US $45.5 billion, a decrease of 2%. It is worth mentioning that Roche Pharmaceuticals' annual performance in mainland China and Hong Kong markets in 2020 increased by 8% compared with the previous year.In response to COVID-19 pandemic, a number of diagnostic kits developed by Roche have obtained emergency use authorization from regulatory agencies; In August last year, Roche also reached a cooperation with Regeneron to jointly develop, produce and sell REGEN-COV-2 (casirivimab and imdevimab combination therapy). Roche is responsible for the sales of these two products outside the United States.<a href=\"https://laohu8.com/S/NVS\">Novartis</a>：Full year revenue487US $100 million，Chinese market achieves double-digit growthOn January 27, Novartis Group released its 2020 full-year financial report, with annual net sales reaching US $48.7 billion, a year-on-year increase of 3%; Core operating profit reached US $15.4 billion, a year-on-year increase of 13%; Sales in the Chinese market achieved double-digit growth. A total of 6 new drugs and indications were approved in China throughout the year, and 8 more products and new indications entered the national medical insurance catalog in 2020.It can be seen from the financial report released by Novartis that innovative drugs including Nuoxinto and Cosenting have become the main engine of its sales, with net sales reaching 39 billion US dollars. \"Despite the challenges posed by COVID-19 pandemic, Novartis delivered outstanding results across all strategic focus areas in 2020, with sales growth and continued improvement in core operating margins for innovative drugs,\" said Novartis Group CEO Wan Sihan.<a href=\"https://laohu8.com/S/MRK\">Merck & Co</a>：Full year revenue480US $100 million，China leads the world in growthOn February 4, Merck announced its 2020 results, with a total annual revenue of US $48 billion, a year-on-year increase of 2%. Among them, the global revenue of the pharmaceutical business was US $43.021 billion, a year-on-year increase of 3%; The pharmaceutical business revenue in China was US $3.534 billion, a year-on-year increase of 13%, making it Merck's best-performing region in the world.According to Merck's financial report, China has become Merck's third largest market in the world outside the United States and Europe, leading the world in growth rate. In the research and development of drugs to fight the new crown, Merck has also continued to make efforts. The novel coronavirus pneumonia oral antiviral drug developed in cooperation with Ridgeback Bio is undergoing phase 2/3 clinical trials for inpatients and outpatients, and is expected to be released in the first quarter of 2021. Interim efficacy data. Merck's 2021 revenue forecast is $51.8-53.8 billion.AbbVie：Full year revenue458.04US $100 million，Humira remains a revenue pillarOn February 3, AbbVie announced its 2020 results. Due to its completion in May 2020<a href=\"https://laohu8.com/S/AGN\">Allergan</a>AbbVie's revenue volume directly soared from US $33.266 billion in 2019 to US $45.804 billion, a year-on-year increase of 37.7%. Among them, the global net income of immune combination products is US $22.153 billion, and the global net income of hematological tumor product portfolio is US $6.651 billion.It can be seen from the financial report that Humira is still AbbVie's revenue pillar. A drug contributed US $19.832 billion, accounting for 43% of AbbVie's entire company revenue.GSK:Full year revenue340.99100 million pounds, the world's first BCMA targeted therapy launched a good startFebruary 3,<a href=\"https://laohu8.com/S/GSK\">Glaxo SmithKline</a>The 2020 financial report was released, with total annual revenue of 34.099 billion pounds (44.059 billion US dollars), a year-on-year increase of 1%; Consumer health care is a business that GSK attaches importance to. In 2019, it absorbed<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>After the assets were divested, the revenue reached 10.033 billion pounds, a year-on-year increase of 12%, which also maintained the growth of GSK's overall company performance. However, its pharmaceutical business revenue in 2019 was 17.056 billion pounds, a decrease of 3%, and its vaccine business revenue was 6.982 billion pounds, a decrease of 2%, both showing a slight decline.In August 2020, Blenrep, as the first BCMA targeted therapy approved in the world, earned US $43 million in revenue from clinical end-of-line therapy applications in just 5 months after its launch. Although the overall situation of the existing business is good, GSK suffered the biggest project research and development setback after returning to the tumor at the end of 2020. GSK disclosed in its annual report that it terminated the phase II OX40 agonist project GSK3174998 due to lack of sufficient evidence of efficacy, and also terminated the development of LAG-3 monoclonal antibody GSK2831781 for the treatment of ulcerative enteritis.<a href=\"https://laohu8.com/S/0O59.UK\">Sanofi</a>：Full year revenue360.41Billion euros, Q4China achieves nearly double-digit growthOn February 5, Sanofi announced its 2020 financial report, with total annual revenue of 36.041 billion euros (US $43.674 billion), a year-on-year decrease of 0.2%. It became the only one among the 14 multinational pharmaceutical companies that experienced a decline. Among them, pharmaceutical business revenue was 25.674 billion euros, a year-on-year increase of 3.1%, vaccine business revenue was 5.973 billion euros, a year-on-year increase of 8.8%, and consumer health care business revenue was 4.394 billion euros, a year-on-year decrease of 1.9%.It can be seen from the financial report that the sales of Dupixent (dupilumab) will increase significantly in 2020, a year-on-year increase of 70%, reaching 3.5 billion euros (4.2 billion US dollars). In the fourth quarter, sales in China achieved nearly double-digit growth, reaching 492 million euros, a year-on-year increase of 9.9%, while its annual sales in China were 2.454 billion euros.Bristol-Myers<a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb</a>：Full year revenue425.18US $100 million, the revenue pillar O drug experienced a decline in performance for the first timeOn February 4, Bristol-Myers Squibb (BMS) announced its 2020 results, with total annual revenue reaching US $42.518 billion, an increase of 62.62%. This substantial increase mainly comes from the completion of the acquisition of Celgene at the end of 2019 and the consolidation of results in 2020. The revenue pillar of Bristol-Myers Squibb, O Pharmaceutical, experienced its first performance decline in 2020, with sales of US $6.992 billion, a 3% decrease from last year. And in the 2020 medical insurance negotiations, O medicine failed to enter China's medical insurance catalog.It can be seen from the financial report that several new BMS drugs approved for marketing in the United States brought in US $138 million in revenue in 2020. They are the world's first red blood cell maturation agent approved in 2019, Reblozyl for the treatment of myelodysplasia, and 2020 Zeposia, which was approved for the treatment of multiple sclerosis in March, and Onureg, a micro-innovative preparation, was approved in September 2020.Pfizer: The total annual revenue was 41.908 billion US dollars, and the performance of lung cancer targeted drugs was goodOn February 2, Pfizer released its 2020 company results, with total annual revenue of US $41.908 billion, a year-on-year increase of 2%. In 2020, sales of 5 Pfizer drugs declined. Among them, the annual sales of etanercept, a rheumatism immunization drug that entered China's National Medical Insurance Catalog in 2020, were US $1.35 billion, a year-on-year decrease of 21%, which was Pfizer's drug with the highest sales decline in 2020.According to the financial report, the lung cancer targeted drug loratinib has achieved good results, with a growth of nearly 80% in 2020, which is the best performing among Pfizer's newly launched drugs. Pfizer's business modules also completed the transformation in 2020. On November 16, Pfizer officially divested its generic drug business unit \"Pfizer Puqiang\" and instead focused on the innovative biopharmaceutical business. Upjohn and Mylan formally merged into a new company, Huizhi, and set up a global center in Shanghai, China.<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>：Full year revenue266.17US $100 million，ChengThe best-performing multinational pharmaceutical company in the Chinese marketOn February 12, AstraZeneca announced its full-year financial statements for 2020. The financial report showed that the full-year revenue was US $26.617 billion, a year-on-year increase of 9%. According to the financial report, its total revenue in China in 2020 reached US $5.373 billion, accounting for 20.2% of AstraZeneca's global revenue. Due to the impact of COVID-19 pandemic, medical insurance negotiations, and volume procurement reduction in drug prices, the growth rate was higher than 2019. There was a sharp decline in 2019 (10% vs 35%), but it is still the best-performing multinational pharmaceutical company in the Chinese market.In terms of specific products, AstraZeneca's star drugs Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), and Farxiga (dapagliflozin) have contributed to AstraZeneca's growth. It has made a huge contribution, bringing in a total revenue of US $10.1 billion.<a href=\"https://laohu8.com/S/AMGN\">Amgen</a>：Full year revenue254.24US $100 million，Double growth in revenue and profitOn February 2, Amgen announced its 2020 results. It achieved total revenue of US $25.424 billion for the year, a year-on-year increase of 9%, mainly due to the expansion transactions and business development in the Chinese and Japanese markets. Sales outside the United States increased to 6 billion. In addition, the annual sales revenue of nearly US $2.2 billion of the psoriasis drug Otezla (Apremilast) acquired from Celgene was combined, and the biosimilar business also performed amazingly.In 2020, Amgen also continued to advance its product pipeline, and the asthma biological drug Tezepelumab was granted the \"breakthrough therapy\" designation by the FDA; The most eye-catching KRAS inhibitor Sotorasib has submitted marketing applications in the United States, Europe, Canada, the United Kingdom, Brazil, and Australia.Gilead：Full year revenue244US $100 million, Remdesivir sold for US $2.811 billionFebruary 4th,<a href=\"https://laohu8.com/S/GILD\">Gilead Sciences</a>The full year 2020 financial report was released. In 2020, product sales for the whole year were US $24.689 billion, a year-on-year increase of 10%. Among them, Veklury (Remdesivir) contributed US $2.811 billion in revenue.Due to the launch of Remdesivir in 2020, total product sales in the fourth quarter of 2020 were US $7.3 billion, an increase of 26% compared with the same period in 2019, and total product sales in 2020 were US $24.4 billion, a year-on-year increase of 10%. In terms of product pipeline, Gilead has abundant reserves in the fields of tumors, antivirals, and inflammatory diseases, with as many as 52 projects in the clinical development stage. In order to enrich the tumor pipeline, Gilead has reached cooperative merger and acquisition transactions with 13 companies in the past two years.<a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a>: Total annual revenue of US $24.54 billion,Double-digit growthOn January 29, Eli Lilly announced its 2020 results, with total annual revenue of US $24.54 billion, a year-on-year increase of 10%. And its sales growth rate is even greater, reaching 15%. According to the financial report, excluding bamlanivimab sales, sales for the whole year of 2020 will increase by 6% and sales will increase by 11%.On the one hand, Eli Lilly's double-digit growth is due to the fact that bamlanivimab received FDA emergency use authorization in November last year for the treatment of mild to moderate COVID-19 patients over 12 years old and adults, contributing US $871 million in revenue, and Baricitinib combined with remdesivir was emergency authorized by the FDA for hospitalized children and adult COVID-19 patients, with revenue increasing by 50%; On the other hand, it is mainly due to the joint development of eight new drugs launched after 2014, contributing a total of US $12.4 billion, accounting for more than 50% of the company's overall revenue.<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>: The total annual revenue is US $19.411 billion, and China's revenue accounts for 11%On February 5, Novo Nordisk announced its 2020 results, with a total annual revenue of US $19.411 billion, a year-on-year increase of 4%. Among them, China's revenue was US $2.154 billion, a year-on-year increase of 9.7%, accounting for 11% of Novo Nordisk's global revenue.The financial report shows that the three major segments of Novo Nordisk's disease business are diabetes, obesity and others (including short stature and hemophilia), accounting for 81%, 4% and 15% of the company's overall revenue respectively. In 2020, the diabetes business revenue will be approximately US $15.66 billion, the weight loss business will be approximately US $857 million, and the hemophilia business will be approximately US $1.477 billion, accounting for approximately 30%, 60%, and 13% of the corresponding global markets respectively.Health Times reporter Wang Aibing/clear up</body></html>","source":"sina_symbol","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Summary of the 2020 financial reports of multinational pharmaceutical companies: Under the epidemic, let me show you how these pharmaceutical companies perform?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSummary of the 2020 financial reports of multinational pharmaceutical companies: Under the epidemic, let me show you how these pharmaceutical companies perform?\n</h2>\n<h4 class=\"meta\">\n\n健康时报客户端2021-02-15 16:14\n\n</h4>\n</header>\n<article>\n<html><body>Original title: Combing the financial reports of multinational pharmaceutical companies in 2020: Under the epidemic situation, let me show you how these pharmaceutical companies perform?In 2020, there was a global pandemic in COVID-19 pandemic. According to the latest data from the website of the World Health Organization, as of 15:35 CET on February 13, the cumulative number of confirmed cases of COVID-19 worldwide reached 108 million. Against this background, what kind of transcripts have multinational pharmaceutical companies handed over? Health Times reporters compiled them based on the 2020 financial reports released by major multinational pharmaceutical companies.<div><img src=\"http://k.sinaimg.cn/n/spider2021215/0/w640h2560/20210215/f1f8-kkciesq5521009.jpg/w720fin.jpg\"/></div><a href=\"https://laohu8.com/S/JNJ\">Johnson Johnson</a>: The total annual revenue was US $82.584 billion, due to the impact of the epidemic, the medical device business revenue dropped significantlyOn January 26, 2021, Johnson & Johnson announced its 2020 results, showing that its total revenue in 2020 was US $82.584 billion, a year-on-year increase of 0.6%; Among them, pharmaceutical business revenue and consumer health care business revenue both increased compared with last year, to US $45.572 billion and US $14.053 billion, respectively, an increase of +8% and 1.1%, but medical device business revenue was only US $22.959 billion, a decrease of 11.6%.Regarding the decline in medical device performance, Johnson & Johnson also said that it was mainly due to COVID-19 pandemic that a large number of surgical operations were delayed. The Health Times reporter also noticed that according to the financial report, Johnson & Johnson's medical device business achieved double-digit growth when the novel coronavirus pneumonia epidemic was well controlled in the fourth quarter.Roche：Full year revenueUS $59.6 billion, Roche Pharmaceuticals' Chinese market is growing steadilyOn February 4, Roche announced its 2020 results, with total annual revenue of US $59.6 billion, a year-on-year increase of 1%, of which pharmaceutical business revenue was US $45.5 billion, a decrease of 2%. It is worth mentioning that Roche Pharmaceuticals' annual performance in mainland China and Hong Kong markets in 2020 increased by 8% compared with the previous year.In response to COVID-19 pandemic, a number of diagnostic kits developed by Roche have obtained emergency use authorization from regulatory agencies; In August last year, Roche also reached a cooperation with Regeneron to jointly develop, produce and sell REGEN-COV-2 (casirivimab and imdevimab combination therapy). Roche is responsible for the sales of these two products outside the United States.<a href=\"https://laohu8.com/S/NVS\">Novartis</a>：Full year revenue487US $100 million，Chinese market achieves double-digit growthOn January 27, Novartis Group released its 2020 full-year financial report, with annual net sales reaching US $48.7 billion, a year-on-year increase of 3%; Core operating profit reached US $15.4 billion, a year-on-year increase of 13%; Sales in the Chinese market achieved double-digit growth. A total of 6 new drugs and indications were approved in China throughout the year, and 8 more products and new indications entered the national medical insurance catalog in 2020.It can be seen from the financial report released by Novartis that innovative drugs including Nuoxinto and Cosenting have become the main engine of its sales, with net sales reaching 39 billion US dollars. \"Despite the challenges posed by COVID-19 pandemic, Novartis delivered outstanding results across all strategic focus areas in 2020, with sales growth and continued improvement in core operating margins for innovative drugs,\" said Novartis Group CEO Wan Sihan.<a href=\"https://laohu8.com/S/MRK\">Merck & Co</a>：Full year revenue480US $100 million，China leads the world in growthOn February 4, Merck announced its 2020 results, with a total annual revenue of US $48 billion, a year-on-year increase of 2%. Among them, the global revenue of the pharmaceutical business was US $43.021 billion, a year-on-year increase of 3%; The pharmaceutical business revenue in China was US $3.534 billion, a year-on-year increase of 13%, making it Merck's best-performing region in the world.According to Merck's financial report, China has become Merck's third largest market in the world outside the United States and Europe, leading the world in growth rate. In the research and development of drugs to fight the new crown, Merck has also continued to make efforts. The novel coronavirus pneumonia oral antiviral drug developed in cooperation with Ridgeback Bio is undergoing phase 2/3 clinical trials for inpatients and outpatients, and is expected to be released in the first quarter of 2021. Interim efficacy data. Merck's 2021 revenue forecast is $51.8-53.8 billion.AbbVie：Full year revenue458.04US $100 million，Humira remains a revenue pillarOn February 3, AbbVie announced its 2020 results. Due to its completion in May 2020<a href=\"https://laohu8.com/S/AGN\">Allergan</a>AbbVie's revenue volume directly soared from US $33.266 billion in 2019 to US $45.804 billion, a year-on-year increase of 37.7%. Among them, the global net income of immune combination products is US $22.153 billion, and the global net income of hematological tumor product portfolio is US $6.651 billion.It can be seen from the financial report that Humira is still AbbVie's revenue pillar. A drug contributed US $19.832 billion, accounting for 43% of AbbVie's entire company revenue.GSK:Full year revenue340.99100 million pounds, the world's first BCMA targeted therapy launched a good startFebruary 3,<a href=\"https://laohu8.com/S/GSK\">Glaxo SmithKline</a>The 2020 financial report was released, with total annual revenue of 34.099 billion pounds (44.059 billion US dollars), a year-on-year increase of 1%; Consumer health care is a business that GSK attaches importance to. In 2019, it absorbed<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>After the assets were divested, the revenue reached 10.033 billion pounds, a year-on-year increase of 12%, which also maintained the growth of GSK's overall company performance. However, its pharmaceutical business revenue in 2019 was 17.056 billion pounds, a decrease of 3%, and its vaccine business revenue was 6.982 billion pounds, a decrease of 2%, both showing a slight decline.In August 2020, Blenrep, as the first BCMA targeted therapy approved in the world, earned US $43 million in revenue from clinical end-of-line therapy applications in just 5 months after its launch. Although the overall situation of the existing business is good, GSK suffered the biggest project research and development setback after returning to the tumor at the end of 2020. GSK disclosed in its annual report that it terminated the phase II OX40 agonist project GSK3174998 due to lack of sufficient evidence of efficacy, and also terminated the development of LAG-3 monoclonal antibody GSK2831781 for the treatment of ulcerative enteritis.<a href=\"https://laohu8.com/S/0O59.UK\">Sanofi</a>：Full year revenue360.41Billion euros, Q4China achieves nearly double-digit growthOn February 5, Sanofi announced its 2020 financial report, with total annual revenue of 36.041 billion euros (US $43.674 billion), a year-on-year decrease of 0.2%. It became the only one among the 14 multinational pharmaceutical companies that experienced a decline. Among them, pharmaceutical business revenue was 25.674 billion euros, a year-on-year increase of 3.1%, vaccine business revenue was 5.973 billion euros, a year-on-year increase of 8.8%, and consumer health care business revenue was 4.394 billion euros, a year-on-year decrease of 1.9%.It can be seen from the financial report that the sales of Dupixent (dupilumab) will increase significantly in 2020, a year-on-year increase of 70%, reaching 3.5 billion euros (4.2 billion US dollars). In the fourth quarter, sales in China achieved nearly double-digit growth, reaching 492 million euros, a year-on-year increase of 9.9%, while its annual sales in China were 2.454 billion euros.Bristol-Myers<a href=\"https://laohu8.com/S/BMY\">Bristol-Myers Squibb</a>：Full year revenue425.18US $100 million, the revenue pillar O drug experienced a decline in performance for the first timeOn February 4, Bristol-Myers Squibb (BMS) announced its 2020 results, with total annual revenue reaching US $42.518 billion, an increase of 62.62%. This substantial increase mainly comes from the completion of the acquisition of Celgene at the end of 2019 and the consolidation of results in 2020. The revenue pillar of Bristol-Myers Squibb, O Pharmaceutical, experienced its first performance decline in 2020, with sales of US $6.992 billion, a 3% decrease from last year. And in the 2020 medical insurance negotiations, O medicine failed to enter China's medical insurance catalog.It can be seen from the financial report that several new BMS drugs approved for marketing in the United States brought in US $138 million in revenue in 2020. They are the world's first red blood cell maturation agent approved in 2019, Reblozyl for the treatment of myelodysplasia, and 2020 Zeposia, which was approved for the treatment of multiple sclerosis in March, and Onureg, a micro-innovative preparation, was approved in September 2020.Pfizer: The total annual revenue was 41.908 billion US dollars, and the performance of lung cancer targeted drugs was goodOn February 2, Pfizer released its 2020 company results, with total annual revenue of US $41.908 billion, a year-on-year increase of 2%. In 2020, sales of 5 Pfizer drugs declined. Among them, the annual sales of etanercept, a rheumatism immunization drug that entered China's National Medical Insurance Catalog in 2020, were US $1.35 billion, a year-on-year decrease of 21%, which was Pfizer's drug with the highest sales decline in 2020.According to the financial report, the lung cancer targeted drug loratinib has achieved good results, with a growth of nearly 80% in 2020, which is the best performing among Pfizer's newly launched drugs. Pfizer's business modules also completed the transformation in 2020. On November 16, Pfizer officially divested its generic drug business unit \"Pfizer Puqiang\" and instead focused on the innovative biopharmaceutical business. Upjohn and Mylan formally merged into a new company, Huizhi, and set up a global center in Shanghai, China.<a href=\"https://laohu8.com/S/AZN\">AstraZeneca</a>：Full year revenue266.17US $100 million，ChengThe best-performing multinational pharmaceutical company in the Chinese marketOn February 12, AstraZeneca announced its full-year financial statements for 2020. The financial report showed that the full-year revenue was US $26.617 billion, a year-on-year increase of 9%. According to the financial report, its total revenue in China in 2020 reached US $5.373 billion, accounting for 20.2% of AstraZeneca's global revenue. Due to the impact of COVID-19 pandemic, medical insurance negotiations, and volume procurement reduction in drug prices, the growth rate was higher than 2019. There was a sharp decline in 2019 (10% vs 35%), but it is still the best-performing multinational pharmaceutical company in the Chinese market.In terms of specific products, AstraZeneca's star drugs Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), and Farxiga (dapagliflozin) have contributed to AstraZeneca's growth. It has made a huge contribution, bringing in a total revenue of US $10.1 billion.<a href=\"https://laohu8.com/S/AMGN\">Amgen</a>：Full year revenue254.24US $100 million，Double growth in revenue and profitOn February 2, Amgen announced its 2020 results. It achieved total revenue of US $25.424 billion for the year, a year-on-year increase of 9%, mainly due to the expansion transactions and business development in the Chinese and Japanese markets. Sales outside the United States increased to 6 billion. In addition, the annual sales revenue of nearly US $2.2 billion of the psoriasis drug Otezla (Apremilast) acquired from Celgene was combined, and the biosimilar business also performed amazingly.In 2020, Amgen also continued to advance its product pipeline, and the asthma biological drug Tezepelumab was granted the \"breakthrough therapy\" designation by the FDA; The most eye-catching KRAS inhibitor Sotorasib has submitted marketing applications in the United States, Europe, Canada, the United Kingdom, Brazil, and Australia.Gilead：Full year revenue244US $100 million, Remdesivir sold for US $2.811 billionFebruary 4th,<a href=\"https://laohu8.com/S/GILD\">Gilead Sciences</a>The full year 2020 financial report was released. In 2020, product sales for the whole year were US $24.689 billion, a year-on-year increase of 10%. Among them, Veklury (Remdesivir) contributed US $2.811 billion in revenue.Due to the launch of Remdesivir in 2020, total product sales in the fourth quarter of 2020 were US $7.3 billion, an increase of 26% compared with the same period in 2019, and total product sales in 2020 were US $24.4 billion, a year-on-year increase of 10%. In terms of product pipeline, Gilead has abundant reserves in the fields of tumors, antivirals, and inflammatory diseases, with as many as 52 projects in the clinical development stage. In order to enrich the tumor pipeline, Gilead has reached cooperative merger and acquisition transactions with 13 companies in the past two years.<a href=\"https://laohu8.com/S/LLY\">Eli Lilly</a>: Total annual revenue of US $24.54 billion,Double-digit growthOn January 29, Eli Lilly announced its 2020 results, with total annual revenue of US $24.54 billion, a year-on-year increase of 10%. And its sales growth rate is even greater, reaching 15%. According to the financial report, excluding bamlanivimab sales, sales for the whole year of 2020 will increase by 6% and sales will increase by 11%.On the one hand, Eli Lilly's double-digit growth is due to the fact that bamlanivimab received FDA emergency use authorization in November last year for the treatment of mild to moderate COVID-19 patients over 12 years old and adults, contributing US $871 million in revenue, and Baricitinib combined with remdesivir was emergency authorized by the FDA for hospitalized children and adult COVID-19 patients, with revenue increasing by 50%; On the other hand, it is mainly due to the joint development of eight new drugs launched after 2014, contributing a total of US $12.4 billion, accounting for more than 50% of the company's overall revenue.<a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>: The total annual revenue is US $19.411 billion, and China's revenue accounts for 11%On February 5, Novo Nordisk announced its 2020 results, with a total annual revenue of US $19.411 billion, a year-on-year increase of 4%. Among them, China's revenue was US $2.154 billion, a year-on-year increase of 9.7%, accounting for 11% of Novo Nordisk's global revenue.The financial report shows that the three major segments of Novo Nordisk's disease business are diabetes, obesity and others (including short stature and hemophilia), accounting for 81%, 4% and 15% of the company's overall revenue respectively. In 2020, the diabetes business revenue will be approximately US $15.66 billion, the weight loss business will be approximately US $857 million, and the hemophilia business will be approximately US $1.477 billion, accounting for approximately 30%, 60%, and 13% of the corresponding global markets respectively.Health Times reporter Wang Aibing/clear up</body></html>\n<div class=\"bt-text\">\n\n\n source：<a href=\"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/jjxw/2021-02-15/doc-ikftpnny6892674.shtml\">健康时报客户端</a>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/93c3dba7c4b0e443e40fe6df5639434d","relate_stocks":{"FXE":"欧元做多ETF-CurrencyShares","PFE":"辉瑞","MRK":"默沙东","EUO":"欧元ETF-ProShares两倍做空"},"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/jjxw/2021-02-15/doc-ikftpnny6892674.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2111006332","content_text":"原标题：跨国药企2020年财报梳理：疫情之下，带你看这些药企表现如何？2020年，新冠疫情全球大流行，据世界卫生组织网站最新数据显示，截止欧洲中部时间2月13日15时35分，全球新冠累计确诊病例达1.08亿。在这样的大背景下，跨国药企们交出了怎样的成绩单，健康时报记者根据各大跨国药企发布的2020年财报进行了整理。强生：全年总收入825.84亿美元，因疫情影响医疗器械业务收入下降明显2021年1月26日，强生公布了2020年业绩，显示其在2020年全年实现总收入为825.84亿美元，同比增长0.6％；其中制药业务收入和消费者保健业务收入较去年均有所增长，分别为455.72亿美元和140.53亿美元，增幅分别为+8％和1.1％，但医疗器械业务收入仅为229.59亿美元，下降11.6％。关于医疗器械业绩的下滑，强生也表示，主要是因为新冠疫情，大量外科手术被延迟。而健康时报记者也注意到，根据财报显示，在第四季度新冠肺炎疫情在中国控制良好的态势下，强生的医疗器械业务获得了2位数的增长。罗氏：全年总收入596亿美元，罗氏制药中国市场稳步增长2月4日，罗氏公布2020年业绩，全年总收入596亿美元，同比增长1%，其中制药业务收入455亿美元，下滑2%。值得一提的是，罗氏制药中国大陆与香港市场2020年全年业绩较上一年增长8%。在应对新冠疫情方面，罗氏开发的多款诊断试剂盒获得了监管机构的紧急使用授权；去年8月，罗氏还与再生元达成一项合作，共同开发、生产和销售REGEN-COV-2(casirivimab和imdevimab组合疗法)，罗氏负责这两个产品在美国以外地区的销售。诺华：全年总收入487亿美元，中国市场实现双位数增长1月27日，诺华集团发布2020年全年财报，全年净销售额达到487亿美元，同比增长3%；核心营业利润达154亿美元，同比增长13%；中国市场销售额实现两位数增长。全年共有6个新药及适应症在中国获批，2020年又有8个产品及新适应症进入国家医保目录。从诺华公布的财报可见，包括诺欣妥、可善挺等内的创新药成为其销售额的主要引擎，净销售额达390亿美元。“尽管新冠疫情带来诸多挑战，但2020年诺华在所有战略重点领域均取得了出色业绩，销售额增长，创新药物的核心营业利润率持续提高。”诺华集团首席执行官万思瀚表示。默沙东：全年总收入480亿美元，中国增速领跑全球2月4日，默沙东公布2020年业绩，全年总收入480亿美元，同比增长2%。其中制药业务全球收入430.21亿美元，同比增长3%；而中国区制药业务收入35.34亿美元，同比增长13%，成为默沙东全球表现最好的地区。据默沙东财报显示，中国已成为默沙东在美国、欧洲以外的全球第三大市场，增速领跑全球。在抗击新冠药物的研发上，默沙东也持续发力，与Ridgeback Bio合作研发的新冠肺炎口服抗病毒药物正在进行对住院和门诊患者的2/3期临床试验，预计将于2021年第一季度公布中期疗效数据。默沙东对2021年的收入预期为518-538亿美元。艾伯维：全年总收入458.04亿美元，修美乐仍是收入支柱2月3日，艾伯维公布2020年业绩。由于其2020年5月完成了对艾尔建的收购，艾伯维的收入体量从2019年的332.66亿美元直接飙升到458.04亿美元，同比增长37.7%。其中免疫组合产品全球净收入221.53亿美元，血液肿瘤产品组合全球净收入为66.51亿美元。从财报可以看出，修美乐（Humira）仍是艾伯维的收入支柱，一个药品贡献了198.32亿美元，在AbbVie整个公司收入中的占比达到43%。GSK：全年总收入340.99亿英镑，全球首个BCMA靶向疗法上市开门红2月3日，葛兰素史克公2020年布财报，全年总收入340.99亿英镑（440.59亿美元），同比增长1%；消费者保健是GSK重视的一块业务，2019年吸收了辉瑞剥离出来的资产之后，收入达到100.33亿英镑，同比增长12%，也维持了GSK整体公司业绩的增长。但其2019年制药业务收入170.56亿英镑，降低3%，疫苗业务收入69.82亿英镑，降低2%，均出现小幅下滑。2020年8月，Blenrep作为全球获批的第一个BCMA靶向疗法，上市短短5个月就在临床末线疗法应用上取得4300万美元的收入。虽然现有业务整体形势良好，但GSK在2020年年底遭遇了重返肿瘤之后的最大项目研发挫折。GSK在年报中披露因为缺乏足够的疗效证据而终止了处于II期的OX40激动剂项目GSK3174998，同时也终止了LAG-3单抗GSK2831781治疗溃疡性肠炎的开发。赛诺菲：全年总收入360.41亿欧元，Q4中国实现近两位数增长2月5日，赛诺菲公布2020年财报，全年总收入360.41亿欧元（436.74亿美元），同比下滑0.2%。成为14家跨国药企中唯一一个出现下滑的企业。其中制药业务收入256.74亿欧元，同比增长+3.1%、疫苗业务收入59.73亿欧元，同比增长+8.8%、消费者保健业务收入43.94亿欧元，同比下降1.9%。 从财报中可以看出，Dupixent（度普利尤单抗）2020年销售大增，同比增长70%，达35亿欧元（42亿美元）。而第四季度中国区销售额实现近两位数增长，达4.92亿欧元，同比增长9.9%，而其在中国全年销售额为24.54亿欧元。百时美施贵宝：全年总收入425.18亿美元，收入支柱O药首次出现业绩下滑2月4日，百时美施贵宝（BMS）公布2020年业绩，全年总收入达到425.18亿美元，增长了62.62%。这一大幅增长主要来自于2019年底完成了对Celgene的收购，并在2020年业绩并表。百时美施贵宝的收入支柱，O药在2020年首次出现业绩下滑，销售额为69.92亿美元，比去年下降了3%。并且在2020年医保谈判中，O药未能进入中国的医保目录。从财报可以看出，BMS几款在美国获批上市的新药在2020年带来了1.38亿美元的收入，分别为2019年获批的全球首个红细胞成熟剂，治疗骨髓增生异常的Reblozyl，2020年3月获批治疗多发性硬化的Zeposia，2020年9月获批的微创新制剂Onureg。辉瑞：全年总收入为419.08亿美元，肺癌靶向药成绩不错2月2日，辉瑞发布2020年公司业绩，全年总收入为419.08亿美元，同比增长2%。2020年，辉瑞公司有5款药物的销量下降。其中，进入2020年中国国家医保目录的风湿免疫的药物依那西普全年的销售额为13.5亿美元，同比下降21%，是辉瑞2020年销售额下降最高的药物。据财报显示，肺癌靶向药劳拉替尼取得了不错的成绩，2020年获得了近80%的增长，是辉瑞新上市药品中表现最好的一个。辉瑞的业务模块也在2020年完成了转变。11月16日，辉瑞正式剥离了仿制药业务部门“辉瑞普强”，转而专注于创新生物药业务。普强和迈蓝正式合并成新公司晖致，并在中国上海设立了全球中心。阿斯利康：全年总收入266.17亿美元，成中国市场表现最好的跨国药企2月12日，阿斯利康公布了2020年全年财务报表，财报显示，全年营收为266.17亿美元，同比增长9%。根据财报显示，其2020年在中国区的总收入达到了53.73亿美元，占阿斯利康全球收入的20.2%，因为受到新冠疫情、医保谈判和带量采购下调药价的影响，增速较2019年有大幅下滑（10% vs 35%），不过依然是中国市场表现最好的跨国药企。就具体产品而言，阿斯利康明星药物Tagrisso（奥希替尼），Lynparza（奥拉帕利）、Imfinzi（度伐利尤单抗）、Farxiga（达格列净）为阿斯利康的增长做出了巨大贡献，合计带来收入101亿美元。安进：全年总收入254.24亿美元，营收及利润实现双增长2月2日，安进公布了2020年业绩，全年实现总收入254.24亿美元，同比增长9%，主要得益于中国和日本市场的扩张交易和业务开拓，美国以外地区销售额增长到60亿美元以上，另外，合并了从Celgene收购的银屑病药物Otezla（阿普斯特）的近22亿美元全年销售收入，以及生物类似药业务的也有惊艳表现。2020年，安进也不断推进产品管线，哮喘生物药Tezepelumab 获得FDA授予的“突破性疗法”认定；最引人瞩目的KRAS抑制剂Sotorasib已经在美国、欧洲、加拿大、英国、巴西、澳大利亚提交了上市申请。吉利德：全年总收入244亿美元，瑞德西韦大卖28.11亿美元2月4日，吉利德科学发布了2020年全年财务报告。2020年全年产品销售额246.89亿美元，同比增长10%。其中Veklury（瑞德西韦）贡献了28.11亿美元的营收。由于2020年瑞德西韦的上市，2020年第四季度产品总销售额为73亿美元，与2019年同期相比增长26％，2020年全年产品销售总额244亿美元，同比增长10％。在研产品管线方面，吉利德在肿瘤、抗病毒、炎症性疾病领域均有丰富的储备，处于临床开发阶段项目多达52个。为了丰富肿瘤管线，过去两年吉利德共与13家公司达成合作并购交易。礼来：全年总收入245.4亿美元，实现双位数增长1月29日，礼来公布2020年业绩，全年总收入245.4亿美元，同比增长10%。而其销量增速更大，达到15%。据财报显示，除去bamlanivimab销售额，2020年全年销售额增长6%，销量增长11%。礼来能够取得双位数的增长一方面是得益于bamlanivimab在去年11月份获得FDA紧急使用授权用于治疗12岁以上及成人轻至中度COVID-19患者，贡献8.71亿美元收入，以及巴瑞替尼联合瑞德西韦获FDA紧急授权用于住院儿童及成人COVID-19患者，收入增长50%；另一方面主要还是在于8款2014年以后上市新药的联合发挥，合计贡献124亿美元，在公司总体收入中的占比已经超过50%。诺和诺德：全年总收入194.11亿美元，中国区收入占11%2月5日，诺和诺德公布2020年业绩，全年总收入194.11亿美元，同比增长4%。其中，中国区收入21.54亿美元，同比增长9.7%，占诺和诺德全球收入的11%。财报显示，诺和诺德疾病业务的三大板块分别是糖尿病、肥胖和其他（包括矮小症、血友病），在公司整体收入中的占比分别为81%，4%和15%。2020年，糖尿病业务收入约156.6亿美元、减肥业务约8.57亿美元、血友病业务96.62约14.77亿美元，在全球相应市场中的份额分别占到了大约30%，60%和13%。健康时报记者王艾冰/整理","news_type":1,"symbols_score_info":{"MRK":0.6,"EURmain":0.68,"PFE":0.68,"FXE":0.6,"MEURmain":0.6,"EUO":0.6}},"isVote":1,"tweetType":1,"viewCount":902,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}